What is HC Wainwright’s Estimate for SLN Q3 Earnings?

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) – Stock analysts at HC Wainwright increased their Q3 2026 earnings per share (EPS) estimates for shares of Silence Therapeutics in a research note issued to investors on Friday, August 14th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.24) for the quarter, up from their previous estimate of ($0.30). HC Wainwright currently has a “Buy” rating and a $75.00 target price on the stock. The consensus estimate for Silence Therapeutics’ current full-year earnings is ($1.08) per share. HC Wainwright also issued estimates for Silence Therapeutics’ Q4 2026 earnings at ($0.30) EPS, FY2026 earnings at ($1.14) EPS, Q1 2027 earnings at ($0.33) EPS, Q2 2027 earnings at ($0.36) EPS, Q3 2027 earnings at ($0.33) EPS, Q4 2027 earnings at ($0.36) EPS, FY2027 earnings at ($1.38) EPS, FY2028 earnings at ($1.53) EPS, FY2029 earnings at ($1.92) EPS and FY2030 earnings at ($1.50) EPS.

Silence Therapeutics (NASDAQ:SLN) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.12). Silence Therapeutics had a negative return on equity of 106.94% and a negative net margin of 8,943.86%.

A number of other research firms have also issued reports on SLN. Weiss Ratings reissued a “sell (d-)” rating on shares of Silence Therapeutics in a research report on Friday, July 17th. Cantor Fitzgerald assumed coverage on shares of Silence Therapeutics in a research note on Wednesday, June 24th. They issued an “overweight” rating on the stock. Finally, Morgan Stanley increased their target price on shares of Silence Therapeutics from $25.00 to $32.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Silence Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $53.50.

Silence Therapeutics Trading Up 4.6%

Shares of Silence Therapeutics stock opened at $14.35 on Tuesday. Silence Therapeutics has a 1 year low of $4.19 and a 1 year high of $17.58. The stock has a 50-day moving average price of $10.26 and a 200 day moving average price of $7.55. The company has a market cap of $678.04 million, a P/E ratio of -11.21 and a beta of 1.39.

Institutional Investors Weigh In On Silence Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Nantahala Capital Management LLC raised its position in Silence Therapeutics by 48.0% during the fourth quarter. Nantahala Capital Management LLC now owns 1,542,427 shares of the company’s stock valued at $9,378,000 after acquiring an additional 500,000 shares in the last quarter. 5AM Venture Management LLC acquired a new position in shares of Silence Therapeutics in the 2nd quarter valued at $5,228,676,000. Millennium Management LLC boosted its position in Silence Therapeutics by 121.0% in the fourth quarter. Millennium Management LLC now owns 659,592 shares of the company’s stock valued at $4,010,000 after buying an additional 361,080 shares in the last quarter. Ishara Investments LP acquired a new position in Silence Therapeutics in the fourth quarter worth $1,459,000. Finally, ADAR1 Capital Management LLC increased its holdings in shares of Silence Therapeutics by 628.2% in the first quarter. ADAR1 Capital Management LLC now owns 172,157 shares of the company’s stock valued at $907,000 after purchasing an additional 148,514 shares in the last quarter. 98.73% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Silence Therapeutics

Here are the key news stories impacting Silence Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its “Buy” outlook and maintained a $75 price target. The firm reduced its projected losses for Q3 and Q4 2026, FY2026, all quarterly periods in 2027, FY2027, FY2028 and FY2030. Its FY2027 EPS estimate improved to a loss of $1.38 from $1.74, while the FY2026 estimate improved to a loss of $1.14 from $1.38. These revisions suggest the analyst expects better-than-previously projected financial performance. Silence Therapeutics analyst estimates
• Positive Sentiment: Options activity was unusually bullish. Investors bought 24,155 call options on August 17, compared with average daily call volume of just 555 contracts—a 4,252% increase. Heavy call buying can signal expectations for further gains, although it may also reflect short-term speculation rather than fundamental conviction.
• Neutral Sentiment: Silence Therapeutics remains unprofitable. HC Wainwright’s estimates still call for losses through 2030, including a $1.08 loss per share for the current year and a $1.53 loss for FY2028. The company’s recent quarterly results also missed consensus expectations, highlighting continued execution and financing risks despite the improved forecasts.
• Negative Sentiment: One longer-term estimate moved in the wrong direction. HC Wainwright lowered its FY2029 EPS forecast to a loss of $1.92 from $1.74, indicating that the path toward profitability remains uncertain.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.